Intraoperative Periarticular Injection May Improve Postoperative Pain Scores and Reduce Opioid Consumption in Arthroscopic Anterior Cruciate Ligament Reconstruction Surgery

This is the authors' abstract. We don't add key points for this paper.

PURPOSE: To evaluate efficacy of an intraoperative periarticular injection (PAI) in improving postoperative outcomes, including pain relief and reducing opioid consumption in patients undergoing arthroscopic anterior cruciate ligament reconstruction (aACLR) with hamstring tendon autograft. METHODS: This prospective, assessor-blinded, two-surgeon clinical trial was conducted from March 20, 2022, to June 20, 2022. A total of 320 patients were initially included, and after screening and exclusions, 300 patients undergoing aACLR were randomized to receive either PAI or were assigned to the nPAI group. Inclusion criteria consisted of patients aged 18 years or older undergoing primary aACLR, with or without a concomitant meniscus procedure for knee instability, who agreed to participate and provided informed consent for randomization into the PAI or nPAI group. The minimum follow-up period was 2 weeks postoperatively. The primary outcome was decreased visual analog scale (VAS) scores and cumulative morphine milligram equivalents (MME). The secondary outcome parameters included decrease in narcotic-related adverse effects. RESULTS: A total of 142 patients in the PAI group and 146 patients in the nPAI group were analyzed. In the PAI group, a lower VAS score at immediate postoperative period and postoperative 4-hour and 24-hour period was observed compared with the nPAI group. Proportions of patients achieving MCID were higher in the PAI group at all time points compared to nPAI. Cumulative morphine consumption was significantly reduced in the PAI group (P < .001). CONCLUSIONS: PAI during aACLR with hamstring autograft significantly improved pain scores and reduced opioid consumption compared to nPAI. Although statistical differences were found, cohort-specific MCID analysis showed a clinically relevant benefit at 24 hours, with 54.2% of the PAI group achieving meaningful pain relief versus 23.3% in the nPAI group. These results suggest that PAI offers time-dependent, patient-specific benefits and supports its role in multimodal analgesia. LEVEL OF EVIDENCE: Level II, randomized controlled trials.